Advertisement

Questions 51–60

  • Yousaf Ali
Chapter

Abstract

This chapter illustrates a variety of different scenarios of rheumatic disease in succinct question and answer format. It contains ten complex cases with potentially unusual diagnoses designed to stimulate thought and further reading in this rapidly evolving specialty.

Keywords

Assessment of rheumatic diseases Complex rheumatology cases Rare rheumatic diseases Rheumatology board exam preparation Rheumatology case studies Study guide for rheumatology 

References

  1. 1.
    Halfdanarson TR, Litzow MR, Murray JA. Hematologic manifestations of celiac disease. Blood. 2007;109(2):412–21.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Petri M, Karlson EW, Cooper DS, Ladenson PW. Autoantibody tests in autoimmune thyroid disease: a case-control study. J Rheumatol. 1991;18(10):1529–31.PubMedGoogle Scholar
  3. 3.
    Terkeltaub RA. Clinical practice. Gout N Engl J Med. 2003;349(17):1647–55.CrossRefPubMedGoogle Scholar
  4. 4.
    Shekelle PG, Newberry SJ, FitzGerald JD, Motala A, O’Hanlon CE, Tariq A, Okunogbe A, Han D, Shanman R. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166(1):37–51. doi: 10.7326/M16-0461. Epub 2016.CrossRefPubMedGoogle Scholar
  5. 5.
    Matsumura R, Kondo Y, Sugiyama T, Sueishi M, Koike T, Takabayashi K, Tomioka H, Yoshida S, Tsuchida H. Immunohistochemical identification of infiltrating mononuclear cells in tubulointerstitial nephritis associated with Sjögren’s syndrome. Clin Nephrol. 1988;30(6):335–40.PubMedGoogle Scholar
  6. 6.
    Moutsopoulos HM, Cledes J, Skopouli FN, Elisaf M, Youinou P. Nephrocalcinosis in Sjögren’s syndrome: a late sequela of renal tubular acidosis. J Intern Med. 1991;230(2):187–91.CrossRefPubMedGoogle Scholar
  7. 7.
    Wrong OM. Immune-related potassium-losing interstitial nephritis: a comparison with distal renal tubular acidosis. QJM. 1993;86(8):513–42.CrossRefPubMedGoogle Scholar
  8. 8.
    Watts RA. Musculoskeletal and systemic reactions to biological therapeutic agents. Curr Opin Rheumatol. 2000;12(1):49–52.CrossRefPubMedGoogle Scholar
  9. 9.
    Bone HG. Nonmalignant complications of Paget’s disease. J Bone Miner Res. 2006;21(Suppl 2):P64–8. ReviewCrossRefPubMedGoogle Scholar
  10. 10.
    Keating GM, Scott LJ. Zoledronic acid: a review of its use in the treatment of Paget’s disease of bone. Drugs. 2007;67(5):793–804.CrossRefPubMedGoogle Scholar
  11. 11.
    O’Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(5):1164–70.CrossRefPubMedGoogle Scholar
  12. 12.
    Curtis JR, Singh JA. The Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care. Clinical therapeutics. 2011;33(6):679–707. doi:10.1016/j.clinthera.2011.05.044.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Clauw DJ. Fibromyalgia: update on mechanisms and management. J Clin Rheumatol. 2007;13(2):102–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Aresté JF, Solé JMN, Vaquero CG, García JV, Escofet DR. Secondary amyloidosis in rheumatoid arthritis. A clinical study of 29 patients. Ann Med Intern. 1999;16(12):6.Google Scholar
  15. 15.
    Voskuyl AE. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology. 2006;45(Suppl 4):iv4–7. ReviewCrossRefPubMedGoogle Scholar
  16. 16.
    Bateman H, Yazici Y, Leff L, Peterson M, Paget SA. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus. 2000;9(7):542–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219–28.CrossRefPubMedGoogle Scholar
  18. 18.
    Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM, McCune WJ. Increased incidence of cervical intraepithelial neoplasiain women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol. 2004;31(9):1763–7.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Yousaf Ali
    • 1
  1. 1.Mount Sinai HospitalNew YorkUSA

Personalised recommendations